Transaction costs and organizational competences: Explaining the governance structure for manufacturing stage

Journal of Technology Management and Innovation

Volumn 7, Issue 1, 2012, Pages 159-174

  Nogueira, Antonio Carlos Lima ^a   Bataglia, Walter ^a  

^a MACKENZIE PRESBYTERIAN UNIVERSITY   (Brazil)

Author keywords

Conceptual framework; Firm boundaries; Pharmaceutical industry

Indexed keywords

EID: 84859834334     PISSN: None     EISSN: 07182724     Source Type: Journal    
DOI: 10.4067/s0718-27242012000100011     Document Type: Article

References (51)

1. ARGYRES, N. & Zenger, T. R., (2011). Capabilities, transaction costs, and firm boundaries: An integrative theory (August 18, 2011). Organization Science, Forthcoming. http://ssrn.com/abstract=1961600. [Accessed December 1st, 2011].
2. BARNEY, J. B. & Hesterly, W. (1996). Organizational economics: Understanding the relationship between organizations and economic analysis. IN: Clegg, S. R., Hardy, C. & Nord, W.R. (eds.) Handbook of organization studies. SAGE Publications, Newbury Park, CA.
3. BASTOS, V. (2006). Laboratórios farmacêuticos oficiais e doenças negligenciadas: perspectivas de política pública. Revista do BNDES, 13 (25), 269-298.
4. BATAGLIA, W. & Meirelles, D. S. (2009). Population ecology and evolutionary economics: toward an integrative model. Management Research, 7 (2): 87-101.
5. BATAGLIA, W., Silva, A. A. & Klement, C. (2011). As dimensões da imitação entre empresas: Um estudo na indústria de transformação brasileira. RAE. Revista de Administração de Empresas, 51 (2): 160-174.
6. Bataglia, W.& Yu, A.S.O. (2008). A sincronização da tomada de decisão estratégica com o planejamento estratégico formal. Revista de Administração Mackenzie, 9 (5): 82-111.
7. BECKER, M.C. (2004). Organizational routines: a review of the literature. Industrial and Corporate Change, 13 (4): 643-677.
8. BIGELOW, L.S. & Argyres, N. (2008). Transaction costs, industry experience and make-or-buy decisions in the population of early U.S. auto firms. Journal of Economic Behavior and Organization, 66 (3-4): 791-807.
9. BOGNER, W. (1996). Drugs to market: Creating value and advantage in the pharmaceutical industry. Oxford: Elsevier Science.
10. CALIARI, T. & Ruiz, R. (2010). Brazilian pharmaceutical industry and generic drugs: the political intentions and the unexpected changes. In Anais do DRUID Summer Conference 2010, Imperial College London Business School, Londres, Jun 2010. http://www2.druid.dk/conferences/viewabstract.php?id=500870&cf=43 [Accessed October 15, 2010].
11. CAPANEMA, L. (2006). A indústria farmacêutica brasileira e a atuação do BNDES. BNDES Setorial, 23: 193-216.
12. COASE, R. H. (1937). The nature of the firm. Economica, 4 (16): 386-405.
13. CORIAT, B; Malerba F & Montobbio, F. (2004). The international performance of European sectorial systems. IN: MALERBA, F. Sectorial systems of innovation: concepts, issues and analyses of six major sectors in Europe. New York: Cambridge University Press.
14. CYERT, R. & March, J. (1963). A behavioural theory of the firm. Englewood Cliffs: Prentice Hall.
15. SERIO, L. C., Bento, R. D., Martins, G. S. & Duarte, A. L. de M. C. (2011). Strategic outsourcing? The Philips case in the LCD tv market. Journal of Technology Management and Innovation, 6 (2): 218-228.
16. DING, J., Xue, Y., Liang, H., Shao, R. & Chen, Y. (2011). From imitation to innovation: A study of China's drug R&D and relevant national policies, Journal of Technology Management and Innovation, 6 (2): 1-12.
17. DOSI, G.; Nelson, R. & Winter, S.G. (2000). Introduction: The nature and dynamics of organizational capabilities. IN DOSI, G.; Nelson, R. & Winter, S.G. Nature and dynamics of organizational capabilities: 1-22. New York: Oxford University Press.
18. DOSI, G. & Teece, D. (1993).Organizational competence and the boundaries of the firm, CCC Working Paper No. 93-11, UC-B, CRM.
19. EISENHARDT, K. & Schoonhoven, C. (1996). Strategic alliance formation in entrepreneurial firms: strategic needs and social opportunities for cooperation. Organizational Science, 7 (2): 136-150.
20. FERREIRA, I. M. P. (2010). A influência das competências organizacionais e do ambiente na formação dos grupos estratégicos no setor farmacêutico brasileiro, segmento de saúde humana. M.Sc Dissertation, São Paulo, SP. Centro de Ciências Sociais Aplicadas, Universidade Presbiteriana Mackenzie. http://www.mackenzie.br. [Accessed July 01, 2010].
21. HENDERSON, R & Cockburn, I. (1994). Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal, 15 (Winter Special Issue): 63-84.
22. Hernández-Cuevas, C.(2007).Collaborative innovation: The future of biopharma. Journal of Technology Management and Innovation, 2 (3): 1-3.
23. HOETKER, G. (2005). How much you know versus how well I know you: selecting a supplier for a technically innovative component. Strategic Management Journal, 26 (1): 75-96.
24. JACOBIDES, M.G. & Winter, S.G. (2005). The coevolution of capabilities and transaction costs: explaining the institutional structure of production. Strategic Management Journal,.26 (5): 395-413.
25. JOSKOW, P. (2005). Vertical integration. IN: ME ́NARD, C & Shirley, M. Handbook of New Institutional Economics: 319-348. Dordrecht: Springer.
26. KLEIN, B., Crawford, R.G., & Alchian, A.A. (1978). Vertical integration, appropriable rents, and the competitive contracting process. Journal of Law and Economics, 21 (2):297-326.
27. KOGUT, B. (1988). Joint venture: theoretical and empirical perspective. Strategic Management Journal, 9 (4): 319-332.
28. KOGUT, B. & Zander, U. (1992). Knowledge of the firm, combinative capabilities, and the replication of technology. Organization Science, 3 (3): 383-397.
29. MACHER, J.T. & Richman, B.D. (2008). Transaction cost economics: an assessment of empirical research in the social sciences. Business and Politics, 10 (1):1-63.
30. MALERBA, F. (2004). Sectorial systems of innovation: concepts, issues and analyses of six major sectors in Europe. New York: Cambridge University Press.
31. MCKELVY, M; Orsenigo, L & Pammolli, F. (2004). Pharmaceuticals analysis through the lens of a sectorial innovation system. IN: MALERBA, F. Sectorial systems of innovation: concepts, issues and analyses of six major sectors in Europe. New York: Cambridge University Press.
32. MÉNARD, C., (2006). Hybrid oganization of production and distribution. Revista de Analisis Economico, 21(2): 25-41.
33. MOMIGLIANO, F. & Balcet, G. (1983). New trends in internationalization: processes and theories: diversified patterns of multinational enterprise and old and new forms of foreign involvement of the firm. Economic Notes, 12 (3): 42-68.
34. MONTEVERDE, K. & Teece, D. (1982). Supplier switching cost and vertical integration in the US automobile industry. Bell Journal of Economics, 13 (1): 206-13.
35. NAKAMURA, K. & Odagiri, H. (2005). R&D boundaries of the firm: an estimation of the double-hurdle model on commissioned R&D, joint R&D, and licensing in Japan. Economics of Innovation and New Technology, 14 (7): 583-615.
36. NELSON, R. & Winter, S. (1982). An evolutionary theory of economic change. Cambridge: Harvard University Press.
37. NOGUEIRA, A. C. L. (2011). Estratégia e estrutura no setor farmacêutico: o caso do Laboratório Aché. In D. S. Meirelles (Ed.), Formação e evolução da grande empresa brasileira: Estudos de caso embasados nas teorias da firma: 219-246. São Paulo: Universidade Presbiteriana Mackenzie.
38. PISANO, G. (1991). The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry. Research Policy, 20 (3): 237-249.
39. POWELL, W.W; Koput, K.W. & Owen-Smith, J., (1996). Interorganizational collaboration and the locus of innovation: network of learning in biotechnology. Administrative Science Quarterly, 41 (1): 116-145.
40. QUENTAL, C.; Abreu, J.C.; Bomtempo, J.V. & Gadelha, C.A.G. (2008). Medicamentos genéricos no Brasil: impactos das políticas públicas sobre a indústria nacional. Ciência e Saúde Coletiva, 13 (Supl.): 619-628.
41. REVE, T. (1990). The firm as a nexus of internal and external contracts. In AOKI, M., Gustafsson, B. & Williamson, O.E. (orgs.) The firm as nexus of treatis: 133 161misctext London: Sage Publications.
42. RUESTER, S., (2010). Recent developments in transaction cost economics. Resource Markets Working Paper No. RM-18. SSRN: http://ssrn.com/abstract=1535903 [Accessed March 02, 2010].
43. RUMELT, R. P. (1982). Towards a strategic theory of the firm. In LAMB, R.B. (ed.) Competitive strategic management: 566-570. Englewood Cliffs: Prentice Hall.
44. SILVA, C. L. & Oliveira, A. (2007). Brazilian industry policy after 1990: focusing on the pharmaceutical industry. Journal of Technology Management and Innovation, 2 (3): 71-84.
45. SIMON, H.A. (1951). A formal theory of the employment relationship. Econometrica, 19 (3): 293-305.
46. TEECE, D.J; Pisano, G. & Shuen, A. (1997) Dynamic capabilities and strategic management. Strategic Management Journal, 18 (7): 509-533.
47. WHO Collaborating Centre for Drug Statistics Methodology (2010), Guidelines for ATC classification and DDD assignment 2011. Oslo.
48. WILLIAMSON, O.E. (1975). Market and hierarchies: analysis and antitrust implications. New York: The Free Press.
49. WILLIAMSON, O.E. (1999). Strategy research: governance and competence perspectives. Strategic Management Journal. 20: 1087-1108.
50. WILLIAMSON, O.E. (1985). The economic institutions of capitalism: firms, markets and relational contracting. New York: The Free Press.
51. WILLIAMSON, O.E. (1979). Transaction cost economics: the governance of contractual relations. Journal of Law and Economics, 22 (12): 233-261.